Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAC-Shield
- Development stage
- Unknown
- Lead developer
- Morinaga Milk Industry
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LAC-Shield is a postbiotic functional ingredient consisting of the heat-killed bacterial strain *Lactobacillus paracasei* MCC1849. Developed by Morinaga Milk Industry, it is designed to support immune function by interacting with immunocytes in the small intestine's Peyer's patches. This interaction stimulates the production of key cytokines, including interleukin-12 (IL-12) and type I interferons, which play critical roles in antiviral and overall immune responses. Clinical research indicates that LAC-Shield may help reduce the risk and severity of common cold symptoms, improve mood states under stress, and enhance the efficacy of influenza vaccinations, particularly in elderly populations. As a heat-killed (non-viable) ingredient, it is highly stable and suitable for use in a wide range of food, beverage, and dietary supplement applications where traditional live probiotics might not survive processing or storage.
- Brand names
- LAC-Shield
- Other names
- Lactobacillus paracasei MCC1849heat-killed Lactobacillus paracasei MCC1849inactivated Lactobacillus paracasei MCC1849
02
Targets
IFNE (Interferon epsilon)IL12 (Interleukin-12)
Beyond the preview
Go deeper on LAC-Shield.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAC-Shield.